Saturday, September 5, 2026

Abaxx Exchange June Volume Beat May Across Every Metric as It Fights Viceroy Short Report

Abaxx Technologies is countering a short-and-distort report from Viceroy Research with a multi-front response: hiring Paul Weiss to investigate the claims and contacting regulators MAS and CIRO. The company says Abaxx Exchange's June 2026 trading volume topped May's on every measure.

LM Salvado
LM Salvado

July 9, 2026

Abaxx Exchange June Volume Beat May Across Every Metric as It Fights Viceroy Short Report
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Viceroy Research published a short-and-distort report targeting Abaxx Technologies, and the company answered within days with data, lawyers, and regulators.1 Abaxx Exchange's June 2026 trading volume surpassed May's across every metric, the company said, using the numbers to counter the credibility attack.1

Abaxx retained law firm Paul Weiss to investigate the allegations in the Viceroy report.1 The exchange also proactively contacted two regulators overseeing its operations: Singapore's Monetary Authority of Singapore (MAS) and Canada's CIRO.1 Reaching out to regulators before they inquire is a defensive move meant to signal transparency rather than concealment.

Abaxx issued a public rebuttal to the short-seller report alongside the regulatory outreach.1 Short-and-distort campaigns typically pair negative claims with a short position, betting the stock drops on the news. Exchanges targeted by such reports often face pressure on both their share price and their reputation with counterparties.

The June volume figures are the centerpiece of Abaxx's counter-narrative. By pointing to trading activity that improved month-over-month across every metric tracked, the exchange is arguing its core business kept functioning normally through the attack.1 Strong volume data gives Abaxx a factual reference point that doesn't depend on how the Paul Weiss investigation concludes.

The situation remains active, with sentiment among market watchers described as mixed but improving.1 The multi-front response — legal investigation, regulator contact, public rebuttal, and volume disclosure — reflects a strategy of moving faster than the allegations can spread. Whether MAS or CIRO take further action, and what Paul Weiss's investigation finds, will shape how the episode affects Abaxx's standing with traders and counterparties going forward.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score2 source documents2 with a live linkVerifiability: Strong
  1. [1]Press releaseGlobeNewswire· June 22, 2026
    Abaxx Continues to Provide Facts Refuting Ongoing Misinformation and Reaffirms Strong Business Fundamentals
  2. [2]Press releaseGlobeNewswire· June 30, 2026
    Raytech Holding Limited Announces Closing of Approximately $6.2 Million Registered Direct Offering of its Ordinary Shares

In this story · Knowledge Files

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Network, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Funding Surge: Capital Floods Fintech, Foundation Models, and Autonomous Systems
A concentrated burst of AI-linked funding on 2026-08-28 pushed well over $1.5B into companies spanning fraud/identity fintech (Socure, which also acquired Fravity), foundation models (Stability AI), AI agents and enterprise tooling (Instinct, Generalist AI, Emerald AI, Owner), and AI-adjacent autonomous/aerospace ventures (Gatik, Regent Craft). The breadth and simultaneity of these rounds signal that investor appetite for AI is not concentrated in a single vertical but is broadening into applied and infrastructure-adjacent domains, with consolidation (Socure-Fravity) beginning alongside fresh capital formation.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,269 source documents archived
Query this data → isubstrate.com